Can COVID Shots Cause Nerve Pain?

COVID vaccines can, in rare cases, cause nerve pain. The evidence comes from case series, population-level surveillance, and observational studies showing that a small number of people develop neuropathic symptoms within days to weeks of vaccination. The types of nerve pain reported range from tingling and burning in the hands and feet to sharp facial pain and shoulder weakness, and they involve different parts of the nervous system. The risk is low enough that it does not change the overall safety calculus for most people, but the phenomenon is real and has been studied seriously enough to deserve a clear look at what the research actually shows.

Small Fiber Neuropathy After Vaccination

The form of nerve pain that has drawn the most clinical attention after COVID vaccination is small fiber neuropathy, a condition where the tiny nerve endings in the skin and organs become damaged. People with this condition typically describe burning, tingling, or stabbing sensations, often in the feet and hands but sometimes spreading to the face or trunk. Some also develop symptoms related to the autonomic nervous system, like dizziness when standing up, heat intolerance, or a racing heartbeat.

An observational study of 23 patients who developed new neuropathic symptoms within a month of COVID vaccination found that all reported sensory symptoms like severe tingling in the face or limbs, and about 60% also had autonomic problems such as positional rapid heart rate. Of the 16 who had skin biopsies on the lower leg, roughly half showed objective evidence of small fiber damage, either through reduced nerve fiber density or abnormal nerve swelling. Immune deposits were found in blood vessel walls of biopsied tissue, suggesting an immune-mediated process rather than a coincidence.¹

A separate case report documented a 39-year-old man with no history of vaccine reactions who developed arm pain and numbness about four months after his first Pfizer dose. Blood testing revealed highly elevated antibodies against a receptor called FGFR3, a protein found on nerve cells. After treatment with intravenous immunoglobulin, a repeat skin biopsy showed his nerve fiber density had returned to normal.² Another case report described a patient whose nerve fiber density improved after immunoglobulin therapy, suggesting the nerve damage was at least partially reversible when the immune attack was brought under control.³

Why Would a Vaccine Damage Nerves?

The leading explanation is that the immune response triggered by vaccination occasionally goes awry and attacks the body’s own nerve tissue. COVID vaccines work by teaching the immune system to recognize the spike protein of SARS-CoV-2. The problem arises when small segments of that spike protein happen to look similar to proteins found on human nerve cells. Research analyzing the protein sequences of coronavirus spike proteins found shared segments with proteins like FGFR3 and myelin protein P2, both of which are found in the peripheral nervous system.⁴ When the immune system builds antibodies against these look-alike sequences, it can inadvertently target nerve tissue. This concept, called molecular mimicry, is a well-established mechanism behind other autoimmune conditions and is not unique to COVID vaccines.

Beyond molecular mimicry, the intense inflammatory response that any effective vaccine provokes can itself create collateral damage. Immune signaling molecules like cytokines and chemokines, which coordinate the body’s defense against the spike protein, can also trigger inflammation around nerve fibers.⁵ In the observational study mentioned earlier, deposits of a complement protein called C4d were found in blood vessel walls near damaged nerves, pointing to an immune-complex-mediated process, essentially the immune system’s own debris lodging in tissues and triggering local inflammation.¹

These mechanisms help explain why the nerve symptoms tend to appear within a few weeks of vaccination, right in the window when the immune response peaks. They also explain why immunosuppressive treatments have shown promise in reversing the damage: if the immune system is the aggressor, calming it down can let the nerves heal.

Vaccine Type Matters for Certain Nerve Conditions

Not all COVID vaccines carry the same neurological risk profile, and this is especially clear for Guillain-Barré syndrome, a condition where the immune system attacks the nerves controlling muscle movement, causing weakness that can spread from the legs upward. GBS is perhaps the most feared neurological complication of any vaccine, and it has been tracked carefully.

Adenoviral vector vaccines, like the AstraZeneca and Johnson & Johnson shots, showed a measurably higher rate of GBS compared to mRNA vaccines. In one U.S. study using the Vaccine Safety Datalink, the GBS rate in the three weeks after the Johnson & Johnson vaccine was about 32 cases per 100,000 person-years, significantly above the expected background rate. For mRNA vaccines, the rate was roughly 1.3 per 100,000 person-years, which was not above background. A head-to-head comparison found the risk after the adenoviral vaccine was about 20 times higher than after mRNA vaccines.⁶

A multinational study found a similar pattern, with the AstraZeneca vaccine associated with a roughly threefold increase in GBS risk in the six weeks after vaccination, while no significant association was found for mRNA vaccines.⁷ A Spanish population study reinforced this, finding GBS incidence after mRNA-based vaccines was about 0.55 per 100,000 doses, compared to 1.57 per 100,000 doses after non-mRNA vaccines. That same study also noted that COVID infection itself carried a higher GBS risk than any vaccine, at about 2.2 per 100,000 infections.⁸

This distinction largely became moot in practice because both the Johnson & Johnson and AstraZeneca vaccines were withdrawn from most markets by 2023, leaving mRNA vaccines as the primary option for boosters. But the data is worth knowing because it illustrates that the vaccine’s delivery platform, not just the spike protein it encodes, plays a role in determining neurological risk.

Shoulder Pain and Parsonage-Turner Syndrome

Some post-vaccination nerve pain is localized near the injection site. Parsonage-Turner syndrome is an uncommon condition in which nerves of the brachial plexus, the nerve network running from the neck through the shoulder and into the arm, become inflamed, causing sudden severe shoulder pain followed by weakness and muscle wasting. Vaccinations of all types have long been recognized as a trigger, with estimates suggesting that a vaccine precedes the onset of Parsonage-Turner syndrome in roughly 4% to 15% of cases.⁹

COVID vaccines are no exception. A search of the U.S. Vaccine Adverse Event Reporting System found 56 reports of Parsonage-Turner syndrome occurring within 30 days of receiving either the Pfizer, Moderna, or Johnson & Johnson vaccines.⁹ A case report described a middle-aged man who developed pain and weakness in his right upper arm five days after an mRNA booster shot, with symptoms persisting for two months before evaluation.¹⁰

The condition can be easily confused with a shoulder injury from the injection itself, which is a separate issue caused by the needle being placed too high on the deltoid and damaging the shoulder joint or bursa. Parsonage-Turner syndrome involves nerve inflammation rather than mechanical damage, and it typically causes weakness in specific muscle groups as the inflamed nerves stop functioning properly. Pain from this condition can last weeks to months, though most patients eventually recover, sometimes incompletely.

Facial Nerve Pain

Trigeminal neuralgia, a condition causing sudden electric-shock-like pain in the face, has been reported in multiple patients after COVID vaccination. One case described a 36-year-old woman who developed severe attacks of left-sided facial pain the day after her third Pfizer dose. She had no prior neurological conditions, and after investigation found no other obvious cause, the neuralgia was attributed to the vaccination.¹¹ Another early report documented a similar case of trigeminal neuritis after a Pfizer vaccination.¹²

These are individual case reports, which means they can establish that the event happens but cannot tell you how often. Trigeminal neuralgia is uncommon but not vanishingly rare in the general population, so proving a causal connection to vaccination, rather than coincidental timing, is inherently difficult. The temporal pattern of onset within days of vaccination and the absence of alternative explanations in these cases gives the association enough plausibility that clinicians now include recent vaccination as a relevant detail in the diagnostic workup for new-onset facial pain.

Shingles Reactivation as an Indirect Route to Nerve Pain

Not all post-vaccination nerve pain comes from the immune system attacking nerves directly. Some comes from the immune disruption reawakening a virus that was already hiding in nerve tissue. Varicella-zoster virus, the virus behind chickenpox, lies dormant in nerve roots for decades after the initial infection. When the immune system is temporarily distracted or shifted, as it is during a vigorous vaccine response, the virus can reactivate and cause shingles, producing blistering rashes and intense burning or stabbing pain along the affected nerve’s path.

A published case described a 68-year-old man who developed a stinging sensation and pain radiating from his right chest to his back five days after his second COVID vaccine dose. Examination revealed the classic vesicular rash of shingles along the T3-T5 nerve paths. The mechanism was attributed to vaccine-induced immunomodulation, a temporary shift in immune priorities that loosened the lid on the dormant virus.¹³

Shingles-related nerve pain can linger long after the rash clears, a condition called postherpetic neuralgia that sometimes persists for months or years. For people who had chickenpox earlier in life, this is worth being aware of, particularly if they have not received the separate shingles vaccine.

How Common Are These Events Overall?

A systematic review that pooled case reports from around the world identified 258 patients with neuromuscular conditions following COVID vaccination. Of those, the majority were Guillain-Barré syndrome (171 cases), followed by Parsonage-Turner syndrome (40 cases), myasthenia gravis (22 cases), facial nerve palsy (19 cases), and small fiber neuropathy (5 cases). The median time from vaccination to symptom onset was less than two weeks across all groups.² These numbers reflect published case reports, not the total number of affected people worldwide, so they undercount the true incidence. Still, set against the billions of COVID vaccine doses administered globally, these figures point to a genuinely rare occurrence.

An important caveat: the small fiber neuropathy count of five in that review almost certainly understates reality. Small fiber neuropathy requires a skin biopsy to confirm, which most patients with vague tingling complaints never receive. The observational study that specifically recruited and tested symptomatic patients found objective evidence in about half of them, suggesting that many cases go undiagnosed or are written off as anxiety or stress.

Treatment Responses and Recovery

One of the more encouraging findings in the research is that many patients with post-vaccination nerve pain improve with immunotherapy, which reinforces the idea that the damage is immune-driven and potentially reversible. In the 23-patient observational study, about 58% of those treated with oral corticosteroids showed complete or near-complete improvement within two weeks, compared to just 9% of those who received no immunotherapy recovering fully within 12 weeks. Three patients who had not improved after months were given intravenous immunoglobulin and saw their symptoms resolve within two weeks.¹

For small fiber neuropathy specifically, the case reports involving FGFR3 antibodies showed that intravenous immunoglobulin not only reduced symptoms but objectively restored nerve fiber density on biopsy.² This matters because it demonstrates the nerves were not permanently destroyed, they were being actively suppressed or attacked by the immune system, and removing that attack let them regrow. Not everyone responds this well, and Guillain-Barré syndrome and Parsonage-Turner syndrome can leave lasting deficits even with treatment. But the overall picture is that early recognition and appropriate treatment substantially improve outcomes.

When Nerve Pain Isn’t Nerve Damage

Researchers have also documented cases where severe neurological symptoms after vaccination, including pain, weakness, and numbness, turned out to have no detectable nerve damage on testing. These fall under the umbrella of functional neurological disorder, where the nervous system produces real and often disabling symptoms without structural injury to the nerves or brain. Two cases were described in which patients developed functional movement problems and functional sensory symptoms after COVID vaccination, driven in part by anxiety, heightened body awareness, and the amplification of normal post-vaccine sensations into something more alarming.¹⁴

This is not the same as saying the symptoms are “all in someone’s head.” Functional neurological disorder causes genuine suffering and impairment, but the treatment pathway is entirely different from immune-mediated neuropathy. Misdiagnosing functional symptoms as autoimmune nerve damage can lead to unnecessary and potentially harmful treatments like immunosuppression, while failing to offer the rehabilitative and psychological approaches that actually help. Recognizing this as a real possibility is important both for clinicians and for patients trying to make sense of their symptoms.

Telling Vaccine Side Effects Apart from Long COVID

Diagnosing post-vaccination nerve pain has been complicated by the fact that the symptoms closely resemble those of long COVID. Both can produce tingling, burning pain, fatigue, brain fog, and autonomic dysfunction. A patient who develops these symptoms weeks after vaccination might also have had an undiagnosed asymptomatic COVID infection around the same time, making it genuinely unclear which exposure caused the problem.¹⁵

The timing and pattern of symptom onset can sometimes help. Vaccine-related neuropathy tends to begin within two weeks of the shot, while long COVID symptoms typically emerge during or shortly after an acute infection. Autoantibody testing, like the FGFR3 antibodies found in the small fiber neuropathy cases, can also point toward an autoimmune mechanism triggered by vaccination rather than chronic viral effects. But there is no single test that definitively separates the two, and in many cases the distinction remains a clinical judgment call. For the patient, the practical difference may be less important than simply getting an accurate diagnosis and the right treatment, whether the trigger was a vaccine or a virus.

Lipid Nanoparticles and the Brain

Some concern has focused on whether the lipid nanoparticles used to deliver mRNA vaccines could themselves contribute to neurotoxicity. Nanoparticles can in theory cross the blood-brain barrier or travel along sensory nerve pathways, and research on nanoparticles in general has shown they can cause oxidative stress and trigger inflammatory responses when they enter the nervous system.¹⁶ However, the nanoparticle literature is largely about industrial or environmental exposures at concentrations far higher and more sustained than a single vaccine injection. The lipid nanoparticles in mRNA vaccines are designed to be biodegradable and are cleared from the body within days. While it remains an area of active study, there is currently no strong clinical evidence linking the nanoparticle component specifically to the nerve pain syndromes described above. The weight of evidence points to the immune response to the spike protein, not the delivery vehicle, as the driver of post-vaccination neuropathy.